| imdusiran (AB-729) / Arbutus |
ACTRN12622000317796: Study Investigating the Safety and Immunogenicity of AB-729 and VTP 300 in Virologically Suppressed CHB Participants |
|
|
| Recruiting | 2 | 40 | | | Arbutus Biopharma, Arbutus Biopharma | Virologically-Suppressed Chronic Hepatitis B | | | | |
NCT04820686: A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection |
|
|
| Terminated | 2 | 65 | Europe, Canada, RoW | VBR, Vebicorvir, ABI-H0731, AB-729, SOC NrtI, Entecavir (ETV), Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide (TAF) | Assembly Biosciences, Arbutus Biopharma Corporation | Chronic Hepatitis B | 03/23 | 03/23 | | |
NCT04980482: Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection |
|
|
| Active, not recruiting | 2 | 43 | US, RoW | AB-729, Peg-IFNα-2a, pegylated interferon alpha 2a | Arbutus Biopharma Corporation | Chronic Hepatitis b | 05/24 | 04/25 | | |
NCT06245291: Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection |
|
|
| Recruiting | 2 | 30 | Europe, RoW | Imdusiran, Durvalumab | Arbutus Biopharma Corporation | Hepatitis B, Chronic | 02/27 | 07/27 | | |
| Not yet recruiting | 2 | 10 | NA | Imdusiran (AB-729) | University of Maryland, Baltimore, Arbutus Biopharma Corporation | Chronic Hepatitis B | 12/26 | 07/27 | | |
ACTRN12619000954123: A Study to Investigate the Safety, Tolerability and Pharmacokinetics, of AB-729 Administered by Subcutaneous Injection to Healthy Subjects (part 1) |
|
|
| Active, not recruiting | 1 | 24 | | | Arbutus Biopharma Corporation, Arbutus Biopharma Corporation | Chronic Hepatitis B Infection | | | | |
ACTRN12620000295943: A Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-729 Administered by Subcutaneous Injection to Subjects with Chronic Hepatitis B Infection |
|
|
| Active, not recruiting | 1 | 96 | | | Arbutus Biopharma Corporation, Arbutus Biopharma Corporation | Chronic Hepatitis B Infection (CHB) | | | | |
ACTRN12619001197123: A Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-729 Administered by Subcutaneous Injection to Subjects with Chronic Hepatitis B Infection |
|
|
| Active, not recruiting | 1 | 167 | | | Arbutus Biopharma Corporation, Arbutus Biopharma Corporation | Chronic Hepatitis B Infection (CHB) | | | | |
NCT06277037: Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729) |
|
|
| Not yet recruiting | N/A | 35 | Europe, US, RoW | Non-interventional | Arbutus Biopharma Corporation | Long Term Follow-up | 08/29 | 10/29 | | |